Gesundheitszentrum Wetterau gGmbH Hochwaldkrankenhaus Bad Nauheim Buergerhospital Friedberg Kreiskrankenhaus Schotten-Gedern — Clinical Trial Site

8 Registered trials

3 Currently recruiting

Organisation

Gesundheitszentrum Wetterau gGmbH Hochwaldkrankenhaus Bad Nauheim Buergerhospital Friedberg Kreiskrankenhaus Schotten-Gedern

Location

Bad Nauheim, Germany

Identifier

ORG-100041310

Address

Chaumontplatz 1, 61231, Germany

Departments

Abt. Gynäkologie Geburtshilfe u. Senologie
Brustzentrum
Frauenklinik, Gynäkologie - Senologie
Gynäkologie
Gynäkologie / onkologische Tagesklinik
Gynäkologische Ambulanz
Gynecology

Clinical trials at this site (8)

Search interface

NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical st… Pending

2024-516734-35-00 triple-negative early breast cancer 5
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/… Recruiting

2025-522484-15-00 ER+/HER2- early breast cancer 5 2026-04-27
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE… Recruiting

2022-500764-35-00 Patients with advanced HER2-negative, hormone receptor 6 2022-10-13
A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu… Ended

2022-500014-26-00 Locally-Advanced unresectable or Metastatic breast canc 5 2022-06-24
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive… Ended

2023-503568-18-00 Early human epidermal growth factor receptor 2 (HER2) p 5 2021-04-13
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati… Ended

2023-508472-11-00 Patients with early breast cancer 5 2018-06-13